Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIORA THERAPEUTICS, INC.BIOR · Entity 85047 | Director · Chief Executive Officer | August 15, 2024 | August 16, 2024 |
| Insight Molecular Diagnostics Inc.OCX · Entity 6631 | Director | July 19, 2019 | July 19, 2019 |
| Lineage Cell Therapeutics, Inc.BTX · Entity 6045 | Director · Co-Chief Executive Officer | July 10, 2018 | July 12, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIORA THERAPEUTICS, INC.
Report date August 15, 2024 · Filed August 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,468,609 |
Reported balance
After 2024-08-15 transaction · row 1
1 source rowRow 1 · 2024-08-15 · Tax withholding · Disposed 70,883 · Balance 1,468,609 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of vested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of vested restricted stock units.
Insight Molecular Diagnostics Inc.
Report date July 19, 2019 · Filed July 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.12 · Expires 2029-07-16 | Direct | 45,000 |
Reported balance
After 2019-07-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-17 · Grant · Acquired 45,000 · Balance 45,000 F1: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
Lineage Cell Therapeutics, Inc.
Report date July 10, 2018 · Filed July 12, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, no par valueSEC Table I · non-derivative | Direct | 101,384 |
Last balance in matching sequence
After 2018-07-10 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-07-10 · Exercise / conversion · Acquired 4,687 · Balance 103,005 F1: Does not include 32,813 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Row 2 · 2018-07-10 · Tax withholding · Disposed 1,621 · Balance 101,384 F2: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,687 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1: Does not include 32,813 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 32,813 |
Reported balance
After 2018-07-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-07-10 · Exercise / conversion · Disposed 4,687 · Balance 32,813 F3: Restricted Stock Units vested on July 10, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Does not include 32,813 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options.
F2: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,687 Restricted Stock Units, the grant of which was previously reported on a Form 4.
F3: Restricted Stock Units vested on July 10, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2024 Filed Aug 16, 2024 16:05 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | Tax withholdingCommon Stock | 70,883 | $0.67 | $47,491.61 |
DisclosureSEC source: 0000950170-24-098048 · ownership.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,468,609 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of vested restricted stock units. Read SEC document |
| February 15, 2024 Filed Feb 15, 2024 16:05 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 819,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015858 · ownership.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,539,492 F1 · shares: Consists of 819,000 restricted stock units, 25% of which will vest on February 15, 2025, with the remaining shares vesting in equal semi-annual installments through February 15, 2028, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 16:21 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 559,450 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-043221 · ownership.xml · nonDerivative · entry 2 MOHANTY ADITYA P. · CIK 0001629819 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720,492 F2 · shares: Consists of 559,450 restricted stock units, 25% of which will vest on August 15, 2024, with the remaining shares vesting in equal semi-annual installments through August 15, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 16:21 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | Tax withholdingCommon Stock | 117,881 | $3.14 | $370,146.34 |
DisclosureSEC source: 0000950170-23-043221 · ownership.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,042 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of vested RSUs. Read SEC document |
| May 15, 2023 Filed May 17, 2023 16:54 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | Tax withholdingCommon Stock | 11,249 | $3.35 | $37,684.15 |
DisclosureSEC source: 0000950170-23-022770 · ownership.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,923 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of vested RSUs. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 21:18 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | Tax withholdingCommon Stock | 22,252 | $2.56 | $56,965.12 |
DisclosureSEC source: 0000899243-23-009035 · doc4.xml · nonDerivative · entry 3 MOHANTY ADITYA P. · CIK 0001629819 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,172 F3 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of vested RSUs. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 21:18 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 44,879 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009035 · doc4.xml · nonDerivative · entry 2 MOHANTY ADITYA P. · CIK 0001629819 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,424 F2 · shares: Consists of 44,879 RSUs, which vested upon grant. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 21:18 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 155,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009035 · doc4.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,545 F1 · shares: Consists of 155,550 restricted stock units ("RSUs"), 25% of which will vest on May 15, 2024, with the remaining shares vesting in equal semi-annual installments through May 15, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:06 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | Disposition to issuerSeries X Preferred Stock | 178 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-23-000967 · doc4.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On November 10, 2022, the Company's board of directors (the "Board") declared a dividend of one one-thousandth of a share of Series X Preferred Stock, par value $0.001 per share (the "Preferred Stock"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on November 21, 2022, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on November 21, 2022. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company. F2 · shares: On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock. F2 · price: On January 3, 2023, in connection with the Company's reverse stock split for the common stock, the shares of Preferred Stock were redeemed automatically in accordance with the certificate of designation of the Preferred Stock. Each share of Preferred Stock was redeemed in consideration for the right to receive an amount equal to $0.001 in cash (rounded to the nearest cent) for each whole share of Preferred Stock. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 21:48 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | Tax withholdingCommon Stock | 175,071 | $0.27 | $47,269.17 |
DisclosureSEC source: 0000899243-22-036078 · doc4.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,799,858 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the release of 353,107 vested restricted stock units on November 15, 2022. Read SEC document |
| May 15, 2022 Filed May 17, 2022 17:19 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 2,495,425 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0000899243-22-018429 · doc4.xml · derivative · entry 2 MOHANTY ADITYA P. · CIK 0001629819 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,495,425 Underlying: Common Stock · 2,495,425 shares Expires 2032-05-15 F2 · deemedExecutionDate: This option represents the right to purchase 2,495,425 shares of the Issuer's common stock, 25% of which will vest on May 15, 2023, with the remaining shares vesting in equal monthly installments through May 15, 2026, subject to the Reporting Person's continued service to the Issuer. F2 · derivative.exercise_date: This option represents the right to purchase 2,495,425 shares of the Issuer's common stock, 25% of which will vest on May 15, 2023, with the remaining shares vesting in equal monthly installments through May 15, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 15, 2022 Filed May 17, 2022 17:19 UTC | BIORA THERAPEUTICS, INC. BIOR · Entity 85047 | GrantCommon Stock | 1,562,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-018429 · doc4.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,974,929 F1 · shares: Consists of 1,562,500 restricted stock units, 25% of which will vest on May 15, 2023, with the remaining shares vesting in equal semi-annual installments through May 15, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 08, 2021 Filed Nov 15, 2021 19:34 UTC | BIORA THERAPEUTICS, INC. PROG · Entity 85047 | GrantStock Option (Right to Buy) · Derivative | 2,086,898 | $0.00 Strike: $3.54 | $0.00 |
DisclosureSEC source: 0000899243-21-044665 · doc4.xml · derivative · entry 2 MOHANTY ADITYA P. · CIK 0001629819 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,086,898 Underlying: Common Stock · 2,086,898 shares Expires 2031-11-08 F2 · deemedExecutionDate: This option represents the right to purchase 2,086,898 shares of the Issuer's common stock, 25% of which will vest on November 8, 2022, with the remaining shares vesting in equal monthly installments through November 8, 2025, subject to the Reporting Person's continued service to the Issuer. F2 · derivative.exercise_date: This option represents the right to purchase 2,086,898 shares of the Issuer's common stock, 25% of which will vest on November 8, 2022, with the remaining shares vesting in equal monthly installments through November 8, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 08, 2021 Filed Nov 15, 2021 19:34 UTC | BIORA THERAPEUTICS, INC. PROG · Entity 85047 | GrantCommon Stock | 1,412,429 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-044665 · doc4.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,412,429 F1 · shares: Represents 1,412,429 restricted stock units, 25% of which will vest on November 15, 2022, with the remaining shares vesting in equal semi-annual installments through November 15, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 17, 2019 Filed Jul 19, 2019 20:31 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 45,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-19-042847 · doc4.xml · derivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-07-16 F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| February 15, 2019 Filed Feb 27, 2019 21:56 UTC | Insight Molecular Diagnostics Inc. OCX · Entity 6631 | GrantOption to Purchase Common Stock · Derivative | 33,750 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001209191-19-014338 · doc4.xml · derivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 33,750 shares Expires 2029-02-14 F1 · derivative.exercise_date: Options shall vest one year from the date of grant, subject to the director's continued service as a director of the Company or a subsidiary from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 23:45 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 4,687 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-042492 · doc4.xml · derivative · entry 3 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,813 Underlying: Common Shares · 4,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Restricted Stock Units vested on July 10, 2018. F3 · derivative.expiration_date: Restricted Stock Units vested on July 10, 2018. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 23:45 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 1,621 | $2.20 | $3,566.20 |
DisclosureSEC source: 0001209191-18-042492 · doc4.xml · nonDerivative · entry 2 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,384 F2 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,687 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1 · balance_after: Does not include 32,813 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 23:45 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 4,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-042492 · doc4.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Does not include 32,813 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| April 10, 2018 Filed Apr 13, 2018 00:39 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 4,688 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-024789 · doc4.xml · derivative · entry 3 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Shares · 4,688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Restricted Stock Units vested on April 10, 2018. F3 · derivative.expiration_date: Restricted Stock Units vested on April 10, 2018. Read SEC document |
| April 10, 2018 Filed Apr 13, 2018 00:39 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 1,622 | $2.49 | $4,038.78 |
DisclosureSEC source: 0001209191-18-024789 · doc4.xml · nonDerivative · entry 2 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,318 F2 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,688 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1 · balance_after: Does not include 37,500 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| April 10, 2018 Filed Apr 13, 2018 00:39 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 4,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-024789 · doc4.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Does not include 37,500 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 23:04 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 200,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001209191-18-020724 · doc4.xml · derivative · entry 2 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2028-03-14 F2 · derivative.exercise_date: One quarter of the options shall vest upon the completion of continuous service from the date of grant until February 1, 2019, and the balance of the options shall vest in 36 equal monthly installments, commencing on February 1, 2019, based upon continued service. Read SEC document |
| January 10, 2018 Filed Jan 13, 2018 02:17 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 4,687 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003498 · doc4.xml · derivative · entry 3 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,188 Underlying: Common Shares · 4,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Restricted Stock Units vested on January 10, 2018. F3 · derivative.expiration_date: Restricted Stock Units vested on January 10, 2018. Read SEC document |
| January 10, 2018 Filed Jan 13, 2018 02:17 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 2,057 | $2.68 | $5,512.76 |
DisclosureSEC source: 0001209191-18-003498 · doc4.xml · nonDerivative · entry 2 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,252 F2 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,687 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1 · balance_after: Does not include 42,188 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| January 10, 2018 Filed Jan 13, 2018 02:17 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 4,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-003498 · doc4.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Does not include 42,188 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| October 10, 2017 Filed Oct 13, 2017 01:35 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 4,688 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056783 · doc4.xml · derivative · entry 3 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 Underlying: Common Shares · 4,688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Restricted Stock Units vested on October 10, 2017. F3 · derivative.expiration_date: Restricted Stock Units vested on October 10, 2017. Read SEC document |
| October 10, 2017 Filed Oct 13, 2017 01:35 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 1,762 | $2.81 | $4,951.22 |
DisclosureSEC source: 0001209191-17-056783 · doc4.xml · nonDerivative · entry 2 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,622 F2 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,688 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1 · balance_after: Does not include 46,875 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| October 10, 2017 Filed Oct 13, 2017 01:35 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 4,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-056783 · doc4.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Does not include 46,875 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 00:22 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | PurchaseCommon Shares, no par value | 7,500 | $2.50 | $18,750.00 |
DisclosureSEC source: 0001209191-17-049877 · doc4.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,696 F1 · balance_after: Does not include Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 23:26 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 4,687 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044963 · doc4.xml · derivative · entry 3 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,563 Underlying: Common Shares · 4,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Restricted Stock Units vested on July 10, 2017. F3 · derivative.expiration_date: Restricted Stock Units vested on July 10, 2017. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 23:26 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 1,762 | $3.09 | $5,444.58 |
DisclosureSEC source: 0001209191-17-044963 · doc4.xml · nonDerivative · entry 2 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,196 F2 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,687 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1 · balance_after: Does not include 51,563 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| July 10, 2017 Filed Jul 12, 2017 23:26 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 4,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044963 · doc4.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,958 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Does not include 51,563 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 21:10 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 650,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001209191-17-038596 · doc4.xml · derivative · entry 2 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Shares · 650,000 shares Expires 2027-06-05 F2 · derivative.exercise_date: One quarter of the options shall vest upon the completion of continuous service from the date of grant until February 1, 2018, and the balance of the options shall vest in 36 equal monthly installments, commencing on February 1, 2018, based upon continued service. Read SEC document |
| April 10, 2017 Filed May 2, 2017 01:18 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionRestricted Stock Units · Derivative | 18,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-029051 · doc4.xml · derivative · entry 3 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,250 Underlying: Common Shares · 18,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Restricted Stock Units vested on April 10, 2017. F3 · derivative.expiration_date: Restricted Stock Units vested on April 10, 2017. Read SEC document |
| April 10, 2017 Filed May 2, 2017 01:18 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Tax withholdingCommon Shares, no par value | 7,046 | $3.33 | $23,463.18 |
DisclosureSEC source: 0001209191-17-029051 · doc4.xml · nonDerivative · entry 2 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,271 F2 · kind: Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 18,750 Restricted Stock Units, the grant of which was previously reported on a Form 4. F1 · balance_after: Does not include 56,250 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
| April 10, 2017 Filed May 2, 2017 01:18 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | Exercise / conversionCommon Shares, no par value | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-029051 · doc4.xml · nonDerivative · entry 1 MOHANTY ADITYA P. · CIK 0001629819 · Director · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Does not include 56,250 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.